Professor Zuguo Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Professor zuguo liu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Professor Zuguo Liu Today - Breaking & Trending Today

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Yizhe Wang , Josh Xu , Zuguo Liu , Katherine Smith , Elizabeth Anderson , Xiamen University , Vp Communications , Xiamen Eye Center , Tarsus Pharmaceuticals , Exchange Commission , Bio Announces Topline Results , Chinese Patients , Professor Zuguo Liu , Principal Investigator , Chief Executive Officer , Mainland China , New Drug Application , Annual Report , Investor Relations , Evoke Canale ,

LianBio (LIAN) Reports Topline Results from Phase 3 LIBRA Trial of TP-03

LianBio (LIAN) Reports Topline Results from Phase 3 LIBRA Trial of TP-03
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Zuguo Liu , Yizhe Wang , Xiamen Eye Center , Xiamen University , Professor Zuguo Liu , Principal Investigator , Chief Executive Officer ,

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial
News provided by
Share this article
Share this article
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI and SUZHOU, China, March 11, 2021 /PRNewswire/ Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye disease (DED) in China.
The purpose of this Phase III clinical trial is to evaluate the effectiveness and safety of Tanfanercept (HBM9036) eye drops (0.25%) compared with placebo in the treatment of moderate-to-severe DED patients in China. This clinical trial is led by Professor Zuguo Liu, Chairman of Asia Dry Eye Society (ADES) and Director of Eye Institute of Xiamen University. ....

Hong Kong , United States , United Kingdom , Macau General , Zuguo Liu , Hanall Biopharma , Jingsong Wang , Eye Institute Of Xiamen University , Asia Dry Eye Society , Professor Zuguo Liu , Eye Institute , Harbour Biomed , Dry Eye Disease , ஹாங் காங் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மக்காவு ஜநரல் , ஆசியா உலர்ந்த கண் சமூகம் , கண் நிறுவனம் , துறைமுகம் பயோமெட் , உலர்ந்த கண் நோய் ,